KR20050086933A - 브롬화수소산에스시탈로프람 및 이의 제조방법 - Google Patents
브롬화수소산에스시탈로프람 및 이의 제조방법 Download PDFInfo
- Publication number
- KR20050086933A KR20050086933A KR1020057011704A KR20057011704A KR20050086933A KR 20050086933 A KR20050086933 A KR 20050086933A KR 1020057011704 A KR1020057011704 A KR 1020057011704A KR 20057011704 A KR20057011704 A KR 20057011704A KR 20050086933 A KR20050086933 A KR 20050086933A
- Authority
- KR
- South Korea
- Prior art keywords
- escitalopram
- disorder
- treatment
- escitalopram hydrobromide
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- WIHMBLDNRMIGDW-BDQAORGHSA-N escitalopram hydrobromide Chemical compound Br.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WIHMBLDNRMIGDW-BDQAORGHSA-N 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 3
- 238000000034 method Methods 0.000 title abstract description 7
- 229960001653 citalopram Drugs 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 229960004341 escitalopram Drugs 0.000 claims description 21
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 21
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 7
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 5
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 5
- 208000032841 Bulimia Diseases 0.000 claims description 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 206010041250 Social phobia Diseases 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000030990 Impulse-control disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 238000011221 initial treatment Methods 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 abstract description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 34
- 229960004592 isopropanol Drugs 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000012458 free base Substances 0.000 description 5
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 5
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 4
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940097411 palm acid Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000001358 L(+)-tartaric acid Substances 0.000 description 1
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 210000000077 angora Anatomy 0.000 description 1
- -1 carboxy organic acids Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001511 high performance liquid chromatography nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200202005 | 2002-12-23 | ||
| DKPA200202005 | 2002-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20050086933A true KR20050086933A (ko) | 2005-08-30 |
Family
ID=32668635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057011704A Ceased KR20050086933A (ko) | 2002-12-23 | 2003-12-18 | 브롬화수소산에스시탈로프람 및 이의 제조방법 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20040167209A1 (enExample) |
| EP (1) | EP1578738B1 (enExample) |
| JP (2) | JP4658613B2 (enExample) |
| KR (1) | KR20050086933A (enExample) |
| CN (1) | CN100349885C (enExample) |
| AR (1) | AR042652A1 (enExample) |
| AT (1) | ATE388947T1 (enExample) |
| AU (1) | AU2003287919B2 (enExample) |
| BR (1) | BR0317623A (enExample) |
| CA (1) | CA2511142A1 (enExample) |
| CY (1) | CY1107451T1 (enExample) |
| DE (1) | DE60319739T2 (enExample) |
| DK (1) | DK1578738T3 (enExample) |
| EA (1) | EA013116B1 (enExample) |
| EG (1) | EG24729A (enExample) |
| ES (1) | ES2298595T3 (enExample) |
| IL (1) | IL169125A0 (enExample) |
| IS (1) | IS2654B (enExample) |
| ME (1) | MEP5808A (enExample) |
| MX (1) | MXPA05005772A (enExample) |
| MY (1) | MY135468A (enExample) |
| NO (1) | NO20053595L (enExample) |
| NZ (1) | NZ540281A (enExample) |
| PE (1) | PE20040924A1 (enExample) |
| PL (1) | PL378275A1 (enExample) |
| PT (1) | PT1578738E (enExample) |
| RS (1) | RS51092B (enExample) |
| TW (1) | TW200501943A (enExample) |
| UA (1) | UA80170C2 (enExample) |
| UY (1) | UY28148A1 (enExample) |
| WO (1) | WO2004056791A1 (enExample) |
| ZA (1) | ZA200504109B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200067152A (ko) * | 2017-10-09 | 2020-06-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 에스시탈로프람의 새로운 염 및 고상형 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE388947T1 (de) * | 2002-12-23 | 2008-03-15 | Lundbeck & Co As H | Escitalopramhydrobromid und ein verfahren zu dessen herstellung |
| US20050137255A1 (en) * | 2002-12-23 | 2005-06-23 | H. Lundbeck A/S | Crystalline escitalopram hydrobromide and methods for preparing the same |
| CA2558198A1 (en) * | 2004-03-05 | 2005-09-15 | H. Lundbeck A/S | Crystalline composition containing escitalopram oxalate |
| TWI347942B (en) | 2005-06-22 | 2011-09-01 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| CA2625835A1 (en) * | 2005-10-14 | 2007-05-10 | Forest Laboratories, Inc. | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
| EA200801080A1 (ru) * | 2005-10-14 | 2009-02-27 | Х. Лундбекк А/С | Стабильные фармацевтические лекарственные формы, содержащие эсциталопрам и бупропион |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| EP2042499B1 (en) * | 2006-07-11 | 2018-06-27 | Mitsubishi Tanabe Pharma Corporation | Salt of a morpholine compound |
| WO2008059514A2 (en) * | 2006-07-31 | 2008-05-22 | Cadila Healthcare Limited | Process for preparing escitalopram |
| FR3006594A1 (fr) * | 2013-06-11 | 2014-12-12 | Sorin Crm Sas | Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire |
| CN108976188B (zh) * | 2017-06-05 | 2022-12-06 | 上海奥博生物医药股份有限公司 | 一种艾司西酞普兰双羟萘酸盐新的制备方法 |
| WO2022153262A1 (en) | 2021-01-18 | 2022-07-21 | Anton Frenkel | Pharmaceutical dosage form |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US34712A (en) * | 1862-03-18 | James h | ||
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| HU228576B1 (en) * | 1998-10-20 | 2013-04-29 | Lundbeck & Co As H | Method for the preparation of citalopram |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| HRP20020344B1 (hr) * | 1999-10-25 | 2010-10-31 | H. Lundbeck A/S | Način priprave citaloprama |
| JP2002020379A (ja) * | 2000-05-02 | 2002-01-23 | Sumika Fine Chemicals Co Ltd | シタロプラム臭化水素酸塩の結晶およびその結晶化方法 |
| US6977306B2 (en) * | 2000-05-02 | 2005-12-20 | Sumitomo Chemical Company, Limited | Citalopram hydrobromide crystal and method for crystallization thereof |
| IES20010693A2 (en) * | 2000-08-10 | 2002-07-10 | Lundbeck & Co As H | Pharmaceutical composition containing citalopram |
| EP1339816B1 (de) * | 2000-12-04 | 2004-08-11 | Westfalia Separator AG | Verfahren zur vorbehandlung von rohölen und rohfetten für eine herstellung von fettsäureestern |
| YU85303A (sh) * | 2001-05-01 | 2006-05-25 | H. Lundbeck A/S | Upotreba enantiomerno čistog escitaloprama |
| AR034612A1 (es) * | 2001-06-25 | 2004-03-03 | Lundbeck & Co As H | Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram |
| ATE388947T1 (de) * | 2002-12-23 | 2008-03-15 | Lundbeck & Co As H | Escitalopramhydrobromid und ein verfahren zu dessen herstellung |
| US20050174782A1 (en) * | 2003-03-25 | 2005-08-11 | Chapman Leonard T. | Flashlight |
-
2003
- 2003-12-18 AT AT03779759T patent/ATE388947T1/de not_active IP Right Cessation
- 2003-12-18 AU AU2003287919A patent/AU2003287919B2/en not_active Ceased
- 2003-12-18 DK DK03779759T patent/DK1578738T3/da active
- 2003-12-18 KR KR1020057011704A patent/KR20050086933A/ko not_active Ceased
- 2003-12-18 JP JP2004561083A patent/JP4658613B2/ja not_active Expired - Lifetime
- 2003-12-18 EP EP03779759A patent/EP1578738B1/en not_active Expired - Lifetime
- 2003-12-18 UA UAA200506077A patent/UA80170C2/uk unknown
- 2003-12-18 ES ES03779759T patent/ES2298595T3/es not_active Expired - Lifetime
- 2003-12-18 WO PCT/DK2003/000902 patent/WO2004056791A1/en not_active Ceased
- 2003-12-18 BR BR0317623-1A patent/BR0317623A/pt not_active IP Right Cessation
- 2003-12-18 EA EA200501046A patent/EA013116B1/ru not_active IP Right Cessation
- 2003-12-18 PT PT03779759T patent/PT1578738E/pt unknown
- 2003-12-18 MX MXPA05005772A patent/MXPA05005772A/es active IP Right Grant
- 2003-12-18 NZ NZ540281A patent/NZ540281A/en not_active Application Discontinuation
- 2003-12-18 PL PL378275A patent/PL378275A1/pl not_active Application Discontinuation
- 2003-12-18 CA CA002511142A patent/CA2511142A1/en not_active Abandoned
- 2003-12-18 DE DE60319739T patent/DE60319739T2/de not_active Expired - Lifetime
- 2003-12-18 ME MEP-58/08A patent/MEP5808A/xx unknown
- 2003-12-18 RS YUP-2005/0487A patent/RS51092B/sr unknown
- 2003-12-18 CN CNB2003801063775A patent/CN100349885C/zh not_active Expired - Fee Related
- 2003-12-22 AR ARP030104777A patent/AR042652A1/es unknown
- 2003-12-22 TW TW092136380A patent/TW200501943A/zh unknown
- 2003-12-22 MY MYPI20034949A patent/MY135468A/en unknown
- 2003-12-23 UY UY28148A patent/UY28148A1/es not_active Application Discontinuation
- 2003-12-23 US US10/746,913 patent/US20040167209A1/en not_active Abandoned
-
2004
- 2004-01-05 PE PE2004000013A patent/PE20040924A1/es not_active Application Discontinuation
-
2005
- 2005-05-17 IS IS7848A patent/IS2654B/is unknown
- 2005-05-20 ZA ZA200504109A patent/ZA200504109B/en unknown
- 2005-06-09 IL IL169125A patent/IL169125A0/en unknown
- 2005-06-22 EG EGNA2005000345 patent/EG24729A/xx active
- 2005-07-25 NO NO20053595A patent/NO20053595L/no not_active Application Discontinuation
-
2008
- 2008-05-02 CY CY20081100470T patent/CY1107451T1/el unknown
-
2010
- 2010-10-20 JP JP2010235287A patent/JP2011037893A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200067152A (ko) * | 2017-10-09 | 2020-06-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 에스시탈로프람의 새로운 염 및 고상형 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011037893A (ja) | 臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法 | |
| AU2001100399A4 (en) | Process for the preparation of pure citalopram | |
| EP1181713B1 (en) | Method for the preparation of pure citalopram | |
| SK512004A3 (en) | Process for the preparation of racemic citalopram and/or S- or R-citalopram by separation of a mixture of R- and S-citalopram | |
| SK13662002A3 (sk) | Spôsob prípravy citalopramu, antidepresívny farmaceutický prostriedok s obsahom citalopramu a medziprodukt | |
| EA005491B1 (ru) | Способ получения циталопрама | |
| US8288568B2 (en) | Process for the preparation of escitalopram | |
| HK1087708B (en) | Escitalopram hydrobromide and a method for the preparation thereof | |
| KR20070083586A (ko) | 시탈로프램 및 에난티오머의 제조 방법 | |
| WO2003080589A1 (en) | Purified citalopram salts | |
| JP2017019727A (ja) | デュロキセチン塩基及びデュロキセチン塩酸塩の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20050621 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20081031 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20101222 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20110228 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20101222 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |